Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /DATA/web/docroots/www.alscience.it/include/multilang.php on line 40
ALScience
WELCOME
About us
This site is dedicated to scientific community working on ALS. Our aim is to optimize researchers time and efforts by providing updated, well organized information on novel findings, available resources and research support.
AriSLA - The Foundation for research on ALS - has been set up to make ALS research investments more effective and efficient, to speed up the clinical research impact e and to provide patients with better care, improved conditions and life expectancy. Its aim is to boost Italian excellencies in basic, clinical and technological research. The Foundation founders are Fondazione Cariplo, Fondazione Telethon, Fondazione Vialli and Mauro and AISLA.

 

 

www.ClinicalTrials.gov: ALS Trials Selection UP DATE

 

ClinicalTrials.gov is the more comprehensive registry and results database of publicly and privately supported clinical studies conducted around the world. It was created as a result of the Food and Drug Administration Modernization Act of 1997 (FDAMA).
AriSLA is pleased to provide a concise review of Amyotrophic Lateral Sclerosis trials currently available on clinicaltrials.gov. 
The alphabetical order list reports both ongoing and completed trials related to a single compound. Trials related to each drug are ordered chronologically from the most recent to the oldest one. 

The review is updated twice a year (june and december) and reports only trials with potentially disease-modifying compounds.

The present version is updated to december 2014. Among the most recent trials you can find IBUDILAST a first-in-class small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. Further, you can find the publication references concerning the last edaravone trial resuls (the reduction of ALSFRS-R was smaller in the edaravone group than in the placebo group, but efficacy of edaravone for treatment of ALS was not demonstrated), and the clnicaltrials.gov report of the preliminary results concerning TUDCA.

 Stem cells ALS clinical trials reginstered on www.clinicaltrials. gov are 27, three of which registered in the last six months (two in Spain and one in Korea)

In the last column, if available, references related to publication or sponsor's communications are reported.

 

 

 

FILE ALLEGATI

Clinicaltrials.gov dec 2014drugs
Clinicaltrials.gov dec 2014 stem cells



     
     
     
Powered by Sofonisba